tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jan 10.
doi: 10.1002/jmv.27584. Online ahead of print.
Generation, Characterization and Protective Ability of Mouse Monoclonal Antibodies Against the HA of A (H1N1) Influenza Virus
Liyan Wang[SUP] 1 2 [/SUP], Fan Yang[SUP] 1 [/SUP], Yixin Xiao[SUP] 1 [/SUP], Bin Chen[SUP] 1 [/SUP], Fumin Liu[SUP] 1 [/SUP], Linfang Cheng[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Nanping Wu[SUP] 1 [/SUP], Haibo Wu[SUP] 1 [/SUP]
Affiliations
Abstract
Influenza virus infections pose a continuous threat to human health. Although vaccines function as a preventive and protective tool, they may not be effective due to antigen drift or an inaccurate prediction of epidemic strains. Monoclonal antibodies (mAbs) have attracted wide attention as a promising therapeutic method for influenza virus infections. In this study, three hemagglutinin (HA)-specific mAbs, named 2A1, 2H4 and 2G2 respectively, were derived from mice immunized with the HA protein from A/Michigan/45/2015(H1N1). The isolated mAbs all displayed hemagglutination inhibition (HAI) activity, and the 2G2 mAb exhibited the strongest neutralization effect. Two amino acid mutations (A198E and G173E), recognized in the process of selection of monoclonal antibody resistant mutants, were located in antigenic site Sb and Ca1 respectively. In prophylactic experiments, all three mAbs could achieve 100% protection in mice infected with a lethal dose of A/Michigan/45/2015 (H1N1). A dose of 1 mg/kg for 2H4 and 2G2 was sufficient to achieve a full protective effect. Therapeutic experiments showed that all three mAbs could protect mice from death if they received the mAb administration at 6 hours post-infection, and 2G2 was still protective after 24 hours. Our findings indicate that these three mAbs may have potential prevention and treatment value in an H1N1 epidemic, as well as in the study of antigen epitope recognition. This article is protected by copyright. All rights reserved.
Keywords: epitope; hemagglutination; influenza H1N1; monoclonal antibody; neutralization.
. 2022 Jan 10.
doi: 10.1002/jmv.27584. Online ahead of print.
Generation, Characterization and Protective Ability of Mouse Monoclonal Antibodies Against the HA of A (H1N1) Influenza Virus
Liyan Wang[SUP] 1 2 [/SUP], Fan Yang[SUP] 1 [/SUP], Yixin Xiao[SUP] 1 [/SUP], Bin Chen[SUP] 1 [/SUP], Fumin Liu[SUP] 1 [/SUP], Linfang Cheng[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Nanping Wu[SUP] 1 [/SUP], Haibo Wu[SUP] 1 [/SUP]
Affiliations
- PMID: 35005794
- DOI: 10.1002/jmv.27584
Abstract
Influenza virus infections pose a continuous threat to human health. Although vaccines function as a preventive and protective tool, they may not be effective due to antigen drift or an inaccurate prediction of epidemic strains. Monoclonal antibodies (mAbs) have attracted wide attention as a promising therapeutic method for influenza virus infections. In this study, three hemagglutinin (HA)-specific mAbs, named 2A1, 2H4 and 2G2 respectively, were derived from mice immunized with the HA protein from A/Michigan/45/2015(H1N1). The isolated mAbs all displayed hemagglutination inhibition (HAI) activity, and the 2G2 mAb exhibited the strongest neutralization effect. Two amino acid mutations (A198E and G173E), recognized in the process of selection of monoclonal antibody resistant mutants, were located in antigenic site Sb and Ca1 respectively. In prophylactic experiments, all three mAbs could achieve 100% protection in mice infected with a lethal dose of A/Michigan/45/2015 (H1N1). A dose of 1 mg/kg for 2H4 and 2G2 was sufficient to achieve a full protective effect. Therapeutic experiments showed that all three mAbs could protect mice from death if they received the mAb administration at 6 hours post-infection, and 2G2 was still protective after 24 hours. Our findings indicate that these three mAbs may have potential prevention and treatment value in an H1N1 epidemic, as well as in the study of antigen epitope recognition. This article is protected by copyright. All rights reserved.
Keywords: epitope; hemagglutination; influenza H1N1; monoclonal antibody; neutralization.